经FDA批准的镜头在两年内可减少近视的发展率高达70%. FDA-approved lenses reduce childhood myopia progression by up to 70% over two years.

根据制造商的数据,FDA批准的Essilor Stellest镜头自9月份以来在美国已经开始销售,可在6至12岁儿童中,在两年内将近视的进展速度减慢70%以上. FDA-approved Essilor Stellest lenses, available in the U.S. since September, can slow myopia progression in children aged 6 to 12 by up to 70% over two years, according to manufacturer data. 镜片的特征是11个同心环,带有微小的上升点,将光线转向减少眼延长,这是近视恶化的一个关键因素。 The lenses feature 11 concentric rings with tiny raised dots that redirect light to reduce eye elongation, a key factor in worsening nearsightedness. 近视影响着30%至40%的美国高中学生,与屏幕时间和关闭工作有关的比率不断上升。 Myopia affects 30% to 40% of U.S. high school students, with rising rates linked to screen time and close-up work. 尽管仍在研究确切的生物机制,但透镜为减少视网膜隔离等长期风险提供了一种非侵入性选择。 While the exact biological mechanism is still under study, the lenses offer a non-invasive option to reduce long-term risks like retinal detachment. 价格为450美元,预计将部分由主要远景保险计划支付。 Priced at $450, they are expected to be partially covered by major vision insurance plans. 独立研究正在进行中,以确认结果。 Independent research is ongoing to confirm results.